Schroder Investment Management Group Trims Stock Position in Haemonetics Co. (NYSE:HAE)

Schroder Investment Management Group lessened its holdings in shares of Haemonetics Co. (NYSE:HAE – Get Rating) by 3.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 952,983 shares of the medical instruments supplier’s stock after selling 30,014 shares during the period. Schroder Investment Management Group owned approximately 1.89% of Haemonetics worth $74,952,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in the business. Martingale Asset Management L P purchased a new position in Haemonetics in the third quarter valued at $261,000. Royal Bank of Canada increased its holdings in Haemonetics by 17.0% in the third quarter. Royal Bank of Canada now owns 174,818 shares of the medical instruments supplier’s stock valued at $12,943,000 after buying an additional 25,406 shares in the last quarter. Duality Advisers LP purchased a new position in Haemonetics in the fourth quarter valued at $426,000. Fox Run Management L.L.C. purchased a new position in Haemonetics in the fourth quarter valued at $990,000. Finally, Amalgamated Bank increased its stake in shares of Haemonetics by 2.6% during the third quarter. Amalgamated Bank now owns 35,575 shares of the medical instruments supplier’s stock worth $2,634,000 after purchasing an additional 916 shares in the last quarter.

Wall Street Analysts Forecast Growth

HAE has been the topic of a number of recent research reports. Barrington Research boosted their price target on shares of Haemonetics from $103.00 to $111.00 in a research report on Friday, May 12th. StockNews.com upgraded shares of Haemonetics from a “buy” rating to a “strong-buy” rating in a report on Thursday. Mizuho boosted their target price on shares of Haemonetics from $110.00 to $115.00 and gave the company a “buy” rating in a report on Wednesday, February 8th. JMP Securities boosted their target price on shares of Haemonetics from $105.00 to $115.00 in a report on Friday, May 12th. Finally, Morgan Stanley upped their price objective on shares of Haemonetics from $84.00 to $88.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 8th. Two research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $103.17.

Haemonetics Trading Up 0.1 %

Shares of HAE stock opened at $83.00 on Friday. The stock has a market cap of $4.19 billion, a price-to-earnings ratio of 37.17, a price-to-earnings-growth ratio of 2.31 and a beta of 0.44. The company has a quick ratio of 2.03, a current ratio of 3.06 and a debt-to-equity ratio of 0.92. Haemonetics Co. has a fifty-two week low of $58.23 and a fifty-two week high of $91.39. The firm’s 50 day moving average price is $82.82 and its two-hundred day moving average price is $81.87.

About Haemonetics

(Get Rating)

Haemonetics Corp. is a global healthcare company, which engages in the development and distribution of hematology products and solutions. It operates through the following segments: Plasma, Blood Center, Hospital, and Corporate. The Plasma segment offers automated plasma collection and donor management software systems.